

31st July 2025

The Manager
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Dear Sirs,
Re : **Scrip Code No.530845**

Sub: **Outcome of the Board Meeting held on 31st July 2025**

In terms of Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with related circulars and notifications, we hereby inform you that the Board of Directors of the Company (the "**Board**") at its meeting held today, i.e. 31st July 2025, *inter alia*, has considered and approved the following:

- a) The Unaudited Financial Results of the Company for the quarter ended 30th June 2025. The financial results along with Limited Review Reports from the Auditor of the Company are attached are attached as **Annexure A**. The Auditors have issued an unmodified report.
- b) Withdrawal of the Draft Letter of Offer dated 30 September 2024, filed with SEBI under the erstwhile SEBI regulations applicable for Rights Issues.
- c) Supersession of the Rights issue approval granted on 9 August 2024 and via a fresh resolution effective immediately, approved the fund raising for an amount not exceeding Rs. 150 crores through the issuance of equity shares on rights basis ("**Rights Issue**") to the eligible equity shareholders of the Company as on Record Date (to be fixed in due course), in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018, as amended and other applicable regulations and subject to necessary approvals including regulatory/statutory approvals, as may be required.

Further, the Board has authorised the Rights Issue Committee to proceed with the Rights Issue forthwith and, *inter alia*, to decide the terms and conditions of the Rights Issue, including but not limited to the appointment of intermediaries, terms of payment, determination of the issue price, Rights entitlement ratio, record date, timing of the rights issue and various other related matters.

We also wish to clarify that the proposal before the Board is not for considering any additional offer and issuance of Equity Shares, but only a fresh approval for the rights issue.

- d) Reconstitution of Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee which will be effective from 21st October 2025:



Name of Committee	Composition after re-constitution	Category
Audit Committee*	Mr. Mukesh Malhotra (Chairman)	Independent Director
	Mr. Cyrus Poonevala (Member)	Independent Director
	Dr. Maya Parihar Malhotra (Member)	Non-Executive Director
Nomination and Remuneration Committee	Mr. Mukesh Malhotra (Chairman)	Independent Director
	Mr. Cyrus Poonevala (Member)	Independent Director
	Dr. Maya Parihar Malhotra (Member)	Non-Executive Director
Stakeholders Relationship Committee	Mr. Mukesh Malhotra (Chairman)	Independent Director
	Mr. Cyrus Poonevala (Member)	Independent Director
	Mr. Jeet Malhotra (Member)	Managing Director & CEO

* Mr. Jeet Malhotra, Managing Director & CEO will be permanent Invitee to the Audit Committee Meetings.

The Board Meeting started at 11.10 am and concluded at 11.45 am.

The trading window for dealing in securities of the Company shall open 48 hours after declaration of Financial Results by the Company for the quarter ended 30th June 2025.

Kindly acknowledge the receipt.

Thanking you,
 Yours faithfully,
 For **SUNSHIELD CHEMICALS LIMITED**

Amit
 Ashok
 Kumashi

Digitally signed
 by Amit Ashok
 Kumashi
 Date: 2025.07.31
 11:53:43 +05'30'

Amit Kumashi
Company Secretary



Independent Auditor's Review Report on Unaudited Financial Results of Sunshield Chemicals Limited for the Quarter Ended June 30, 2025, pursuant to Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

**To the Board of Directors of
Sunshield Chemicals Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sunshield Chemicals Limited** ("the Company") for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on July 31, 2025, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the accompanying Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Mistry Bhavan, 3rd Floor, Dinshaw Vachha Road, Churchgate, Mumbai 400 020. Tel: +91 22 6623 0600

501-502, Narain Chambers, M.G. Road, Vile Parle (E), Mumbai 400 057. Tel: +91 22 6250 7600

Website: www.cnkindia.com

MUMBAI | CHENNAI | VADODARA | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | KOLKATA | DUBAI | ABU DHABI

4. Based on our review conducted, as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 (as amended) read with relevant rules issued thereunder and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **C N K & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W100036



Diwakar Sapre

Partner

Membership No. 040740

UDIN: 25040740BMIGPJ5020

Date: July 31, 2025

Place: Mumbai



SUNSHIELD CHEMICALS LIMITED

Regd. Office: 1501-A, Universal Majestic, P.L. Lokhande Marg, behind RBK International School, Chembur-West, Mumbai-400 043

Corporate Identity Number : L99999MH1986PLC041612

Phone No.25550126

E Mail : investorservices@sunshieldchemicals.com Website: www.sunshieldchemicals.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

Rs. In Lakhs (except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2025 Unaudited	Mar 31, 2025 Unaudited	June 30, 2024 Unaudited	Mar 31, 2025 Audited
1	Revenue from operations	11,388	11,031	7,796	36,579
2	Other income	146	93	30	315
3	Total Income (1+2)	11,534	11,124	7,826	36,894
4	Expenses				
	(a) Cost of materials consumed	8,699	7,932	5,340	26,594
	(b) Purchase of stock-in-trade	72	116	327	787
	(c) Changes in inventories of finished goods and work-in-progress	(356)	338	(49)	(317)
	(d) Employee benefits expense	564	519	468	1,908
	(e) Finance costs	227	235	204	910
	(f) Depreciation	265	252	217	977
	(g) Other expenses	1,147	974	940	4,231
	Total expenses	10,618	10,366	7,447	35,090
5	Profit before tax (3-4)	916	758	379	1,804
6	Tax expense:				
	Current tax	227	178	80	395
	Prior year tax adjustment	-	(11)	-	7
	Deferred tax	7	17	(102)	(55)
	Total tax expense	234	184	(22)	347
7	Profit for the period/ year (5-6)	682	574	401	1,457
8	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurements of post-employment benefit obligation	(7)	5	(11)	(27)
	Income tax related to items that will not be reclassified to profit or loss	2	(1)	3	7
9	Total Comprehensive Income for the period/year (7+8)	677	578	393	1,437
10	Paid up equity share capital (face value of Rs.10/- each)	735	735	735	735
11	Other Equity				8,834
12	Earnings per equity share (of Rs. 10/- each) (not annualised in quarters)				
	Basic and diluted	9.28	7.81	5.45	19.81

Notes :

- The aforesaid financial results of Sunshield Chemical Limited (the "Company") were reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its meeting held on July 31, 2025. The Statutory Auditors have carried out a Limited Review and expressed an unmodified opinion on the aforesaid results.
- The aforesaid financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter.
- The Company's management, pursuant to Ind AS 108 - Operating Segments, has concluded that the Company has only one reportable segment which is Speciality Chemicals. Accordingly, no separate disclosures of segment information have been made.
- Pursuant to approval by the Board of Directors at its meeting held on 9th August 2024, the Company had filed Draft Letter of Offer ("DLOF") with Securities & Exchange Board of India (SEBI) on September 30, 2024. Subsequently on March 08, 2025, SEBI introduced amended regulations in relation to rights issues, effective April 07, 2025 ("Amended Rights Issue Regulations"). With a view to expedite the process, the Company has decided to withdraw the DLOF and file a fresh application under the Amended Rights Issue Regulations. The expenditure of Rs. 71.33 lakhs incurred till June 30, 2025, in connection with the proposed Rights Issue is included under the head Other Current assets as Prepaid expenses. The same will be charged to Securities premium account on completion of Right issue of Equity shares.



Place: Mumbai
Date: July 31, 2025

For and on behalf of the Board of Directors
SUNSHIELD CHEMICALS LIMITED

Jeet Malhotra
Managing Director & CEO
DIN: 07208234

